Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Intravitreal Aflibercept Injection (IAI) Administered in a Treat and Extend Fashion in Patients With Center Involved Diabetic Macular Edema (DME) Previously Managed With 0.3 mg Intravitreal Ranibizumab

NCT03059277 is registered in ClinicalTrials.gov with Southeast Clinical Research Associates, LLC as lead sponsor.

NCT NCT03059277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03059277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Intravitreal Aflibercept Injection (IAI) Administered in a Treat and Extend Fashion in Patients With Center Involved Diabetic Macular Edema (DME) Previously Managed With 0.3 mg Intravitreal Ranibizumab
Lead sponsor
Southeast Clinical Research Associates, LLC
Phase
Phase 4
Overall status
Withdrawn
Start date
June 1, 2018
Completion date
September 30, 2020
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema